Siemens Healthineers faces a potential €500 million tariff burden this fiscal year as it prepares for a major corporate restructuring, with its first-quarter 2026 results revealing a mixed performance and a weakening diagnostics market in China.
The medical technology firm, headquartered in Erlangen, Germany, is navigating a complex financial landscape. Approximately 40% of its revenue originates in the United States, whereas a significant portion of its costs are denominated in euros. This creates substantial exposure to U.S. Tariff policies and the strength of the euro, which diminishes the value of earnings generated abroad when converted back to its reporting currency. Despite these headwinds, Siemens Healthineers is maintaining its full-year guidance, projecting comparable revenue growth of 5 to 6 percent and adjusted basic earnings per share between €2.20 and €2.40.
First-quarter results for fiscal 2026, released earlier this year, showed overall revenue growth of 3.8 percent. This growth was largely driven by the Imaging and Precision Therapy divisions. However, the Diagnostics segment experienced a contraction of roughly 3 percent, primarily due to challenges in the Chinese market.
A state-led anti-corruption campaign in China has triggered a shift towards centralized, volume-based procurement, coupled with reductions in reimbursement rates. These factors are exerting significant pressure on the diagnostics business within the country. Jerry Wang, head of Siemens Healthineers’ China operations since 2018, has acknowledged the challenges presented by the evolving market dynamics, according to a company press release from October 2022.
Internally, Siemens Healthineers is responding to these market forces with a focus on digitalization. The company, in collaboration with Ki Reply and Data Reply, has developed an artificial intelligence platform called “Cerebra,” designed to provide real-time insights to marketing and sales teams. This platform has since evolved into an “Agent Factory,” a system that standardizes the deployment of specialized AI agents, aiming to create a scalable foundation for broader automation initiatives.
Concurrently, Siemens Healthineers is preparing for full independence from its parent company, Siemens AG. Siemens AG intends to spin off approximately 30% of its Siemens Healthineers shares directly to its shareholders, relinquishing its controlling majority stake. Detailed plans regarding the structure and timeline for this separation are expected in early April. The company points to its Investment-Grade rating from Moody’s as a foundation for its future financial independence, as reported by Siemens Healthineers.
The upcoming second-quarter report, scheduled for release on May 7, will be a critical test for the company. It will need to demonstrate a stabilization of the Chinese diagnostics business and provide evidence that tariff costs are not further eroding targeted growth. The company’s shares are currently trading near their 52-week low, approximately 30% below their peak from late March 2025.
